GSK3527497 is a potent and selective inhibitor of Transient Receptor Potential Vanilloid-4 (TRPV4) with IC50 = 12 nM) for the treatment of heart failure and respiratory diseases. GSK3527497 is a preclinical candidate suitable for orally bioavailable and iv administration that is projected to inhibit TRPV4 effectively in patients from a low daily clinical dose. References: Brooks CA, Barton LS, Behm DJ, Brnardic E, Costell M, Holt DA, Jolivette LJ, Matthews JM, McAtee JJ, McCleland BW, Patterson JR, Pero JE, Rivero RA, Roethke TJ, Sanchez RM, Shenje R, Terrell LR, Lawhorn BG. Discovery of GSK3527497: A candidate for the inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4). J Med Chem. 2019 Sep 18. doi: 10.1021/acs.jmedchem.9b01247. [Epub ahead of print] PubMed PMID: 31532662.

纯度：≥98%

CAS：2215855-51-7